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Abstract
This collection presents six case studies on the ethics of mental health research, written by 
scientific researchers and ethicists from around the world. We publish them here as a resource for 
teachers of research ethics and as a contribution to several ongoing ethical debates. Each consists 
of a description of a research study that was proposed or carried out and an in-depth analysis of 
the ethics of the study.
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Building Global Capacity in Mental Health Research
According to the World Health Organization (WHO), there are more than 450 million 
people with mental, neurological, or behavioral problems worldwide (WHO, 2005a). Mental 
health problems are estimated to account for 13% of the global burden of disease, 
principally from unipolar and bipolar depression, alcohol and substance-use disorders, 
schizophrenia, and dementia. Nevertheless, in many countries, mental health is accorded a 
low priority; for example, a 2005 WHO analysis found that nearly a third of low-income 
countries who reported a mental health budget spent less than 1% of their total health budget 
on mental health (WHO, 2005b).
Despite the high burden of disease and some partially effective treatments that can be 
implemented in countries with weaker healthcare delivery systems (Hyman et al., 2006), 
there exist substantial gaps in our knowledge of how to treat most mental health conditions. 
A 2007 Lancet Series entitled Global Mental Health claimed that the “rudimentary level of 
mental health-service research programmes in many nations also contributes to poor 
delivery of mental health care” (Jacob et al., 2007). Its recommendations for mental health 
research priorities included research into the effects of interactions between mental health 
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and other health conditions (Prince et al., 2007), interventions for childhood developmental 
disabilities (Patel et al., 2007), cost-effectiveness analysis, the scaling up of effective 
interventions, and the development of interventions that can be delivered by nonspecialist 
health workers (Lancet Global Mental Health Group, 2007). All of these priorities require 
research in environments where the prevailing health problems and healthcare services 
match those of the populations the research will benefit, which suggests that research must 
take place all around the world. Similarly, many of the priorities identified by the Grand 
Challenges in Mental Health Initiative require focus on local environments, cultural factors, 
and the health systems of low- and middle-income countries. All the challenges “emphasize 
the need for global cooperation in the conduct of research” (Collins et al., 2011).
Notwithstanding the need for research that is sensitive to different social and economic 
contexts, the trend of outsourcing to medical research to developing countries shows no sign 
of abating (Thiers et al., 2008). Consequently, a substantial amount of mental health 
research will, in any case, take place in low- and middle-income countries, as well as rich 
countries, during the next few years.
The need for local research and the continuing increase in the international outsourcing of 
research imply that there is a pressing need to build the capacity to conduct good quality 
mental health research around the world. However, the expansion of worldwide capacity to 
conduct mental health research requires more than simply addressing low levels of funding 
for researchers and the imbalance between the resources available in rich and poor countries. 
People with mental health disorders are often thought to be particularly vulnerable subjects. 
This may be a product of problems related to their condition, such as where the condition 
reduces the capacity to make autonomous decisions. It may also result from social 
conditions because people with mental disorders are disproportionately likely to be poor, are 
frequently stigmatized as a result of their condition, and may be victims of human rights 
abuses (Weiss et al., 2001; WHO, 2005a). As a result, it is vitally important that the 
institutional resources and expertise are in place for ensuring that this research is carried out 
ethically.
Discussion at a special session at the 7th Global Forum on Bioethics in Research revealed 
the perception that many mental health researchers are not very interested in ethics and 
showed up a lack of ethics resources directly related to their work. This collection of case 
studies in the ethics of mental health research responds to that gap.
This collection comprises six case studies written by contributors from around the world 
(Table 1). Each describes a mental health research study that raised difficult ethical issues, 
provides background and analysis of those issues, and draws conclusions about the ethics of 
the study, including whether it was ethical as it stood and how it ought to be amended 
otherwise. Three of the case studies are written by scientists who took part in the research 
they analyzed. For these cases, we have asked scholars independent of the research to write 
short commentaries on them. It is valuable to hear how the researchers themselves grapple 
with the ethical issues they encounter, as well as to hear the views of people with more 
distance from the research enterprise. Some of the ethical issues raised here have not been 
discussed before in the bioethics literature; others are more common concerns that have not 
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received much attention in the context of international research. The case studies are 
intended to both expand academic discussion of some of the key questions related to 
research into mental health and for use in teaching ethics.
Case studies are an established teaching tool. Ethical analyses of such cases demonstrate the 
relevance of ethics to the actual practice of medical research and provide paradigmatic 
illustrations of the application of ethical principles to particular research situations. Concrete 
cases help generate and guide discussion and assist students who have trouble dealing with 
ethical concepts in abstraction. Through structured discussion, ethical development and 
decision-making skills can be enhanced. Moreover, outside of the teaching context, case 
study analyses provide a means to generate and focus debate on the relevant ethical issues, 
which can both highlight their importance and help academic discussion to advance.
People working in mental health research can benefit most from case studies that are 
specific to mental health. Even though, as outlined below, many of the same ethical 
problems arise in mental health research as elsewhere, the details of how they arise are 
important. For example, the nature of depression and the variation in effectiveness of 
antidepressive medication make a difference to how we should assess the ethics of placebo-
controlled trials for new antidepressants. Moreover, seeing how familiar ethical principles 
are applied to one's own research specialty makes it easier to think about the ethics of one's 
own research. The cases in this collection highlight the commonalities and the variation in 
the ethical issues facing researchers in mental health around the world.
The current literature contains some other collections of ethics case studies that may be 
useful to mental health researchers. I note four important collections here, to which 
interested scholars may want to refer. Lavery et al.'s (2007) Ethical Issues in International 
Bio-medical Research provides in-depth analyses of ethically problematic research, mostly 
in low- and middle-income countries, although none of these cases involve mental health. 
Cash et al.'s (2009) Casebook on Ethical Issues in International Health Research also 
focuses on research in low- and middle-income countries, and several of the 64 short case 
descriptions focus on populations with mental health problems. Two further collections 
focus on mental health research, in particular. Dubois (2007) and colleagues developed short 
and longer US-based case studies for teaching as part of their “Ethics in Mental Health 
Research” training course. Finally, Hoagwood et al.'s (1996) book Ethical Issues in Mental 
Health Research with Children and Adolescents contains a casebook of 61 short case 
descriptions, including a few from outside the United States and Western Europe. For 
teachers and academics in search of more case studies, these existing collections should be 
very useful. Here, we expand on the available resources with six case studies from around 
the world with extended ethical analyses.
The remainder of this introduction provides an overview of some of the most important 
ethical issues that arise in mental health research and describes some of the more significant 
ethics guidance documents that apply.
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Ethical Issues in Mental Health Research
The same principles can be applied in assessing the ethics of mental health research as to 
other research using human participants (Emanuel et al., 2000). Concerns about the social 
value of research, risks, informed consent, and the fair treatment of participants all still 
apply. This means that we can learn from the work done in other areas of human subjects 
research. However, specific research contexts make a difference to how the more general 
ethical principles should be applied to them. Different medical conditions may require 
distinctive research designs, different patient populations may need special protections, and 
different locations may require researchers to respond to study populations who are very 
poor and lack access to health care or to significant variations in regulatory systems. The 
ethical analysis of international mental health research therefore needs to be tailored to its 
particularities.
Each case study in this collection focuses on the particular ethical issues that are relevant to 
the research it analyzes. Nevertheless, some issues arise in multiple cases. For example, 
questions about informed consent arise in the context of research with stroke patients, with 
students, and with other vulnerable groups. To help the reader compare the treatment of an 
ethical issue across the different case studies, the ethical analyses use the same nine 
headings to delineate the issues they consider. These are social value, study design, study 
population, informed consent, risks and benefits, confidentiality, post-trial obligations, legal 
versus ethical obligations, and oversight.
Here, I focus on five of these ethical issues as they arise in the context of international 
mental health research: (1) study design, (2) study population, (3) risks and benefits, (4) 
informed consent, and (5) post-trial obligations. I close by mentioning some of the most 
important guidelines that pertain to mental health research.
Study Design
The scientific design of a research study determines what sort of data it can generate. For 
example, the decision about what to give participants in each arm of a controlled trial 
determines what interventions the trial compares and what questions about relative safety 
and efficacy it can answer. What data a study generates makes a difference to the ethics of 
the study because research that puts human beings at risk is ethically justified in terms of the 
social value of the knowledge it produces. It is widely believed that human subject research 
without any social value is unethical and that the greater the research risks to participants, 
the greater the social value of the research must be to compensate (Council for International 
Organizations of Medical Sciences [CIOMS], 2002; World Medical Association, 2008). 
However, changing the scientific design of a study frequently changes what happens to 
research participants, too. For example, giving a control group in a treatment trial an existing 
effective treatment rather than placebo makes it more likely that their condition will improve 
but may expose them to adverse effects they would not otherwise experience. Therefore, 
questions of scientific design can be ethically very complex because different possible 
designs are compared both in terms of the useful knowledge they may generate and their 
potential impact on participants.
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One of the more controversial questions of scientific design concerns the standard of care 
that is offered to participants in controlled trials. Some commentators argue that research 
that tests therapeutic interventions is only permissible if there is equipoise concerning the 
relative merits of the treatments being compared, that is, there are not good reasons to think 
that participants in any arm of the trial are receiving inferior treatment (Joffe and Truog, 
2008). If there is not equipoise, the argument goes, then physician-researchers will be 
breaching their duty to give their patients the best possible care (Freedman, 1987).
The Bucharest Early Intervention Project (BEIP) described in the case study by Charles 
Zeanah was a randomized controlled trial comparing foster care with institutional care in 
Bucharest, Romania. When designing the BEIP, the researchers wrestled with the issue of 
whether there was genuine equipoise regarding the relative merits of institutional and foster 
care. One interpretation of equipoise is that it exists when the professional community has 
not reached consensus about the better treatment (Freedman, 1987). Childcare professionals 
in the United States were confident that foster care was superior, but there was no such 
confidence in Romania, where institutional care was the norm. Which, then, was the relevant 
professional community?
The equipoise requirement is justified by reference to the role morality of physicians: for a 
physician to give her patient treatment that she knows to be inferior would violate principles 
of therapeutic beneficence and nonmaleficence. As a result, the equipoise requirement has 
been criticized for conflating the ethics of the physician-patient relationship with the ethics 
of the researcher-participant relationship (Miller and Brody, 2003). According to Miller and 
Brody (2003), provided that other ethical requirements are met, including an honest null 
hypothesis, it is not unethical to assign participants to receive treatment regimens known to 
be inferior to the existing standard of care.
A subset of trial designs that violate equipoise are placebo-controlled trials of experimental 
treatments for conditions for which proven effective treatments already exist. Here, there is 
not equipoise because some participants will be assigned to placebo treatment, and ex 
hypothesi there already exists treatment that is superior to placebo. Even if we accept Miller 
and Brody's (2003) argument and reject the equipoise requirement, there remain concerns 
about these placebo-controlled trials. Providing participants with less effective treatment 
than they could get outside of the trial constitutes a research risk because trial participation 
makes them worse off. Moreover, on the face of it, a placebo-controlled trial of a novel 
treatment of a condition will not answer the most important scientific question about the 
treatment that clinicians are interested in: is this new treatment better than the old one? 
Consequently, in situations where there already exists a standard treatment of a condition, it 
has generally been considered unethical to use a placebo control when testing a new 
treatment, rather than using the standard treatment as an active-control (World Medical 
Association, 2008).
Some psychiatric research provides scientific reasons to question a blanket prohibition on 
placebo-controlled trials when an effective intervention exists. For example, it is not unusual 
for antidepressive drugs to fail to show superiority to placebo in any given trial. This means 
that active-control trials may seem to show that an experimental drug is equivalent in 
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effectiveness to the current standard treatment, when the explanation for their equivalence 
may, in fact, be that neither was better than placebo. Increasing the power of an active-
control trial sufficiently to rule out this possibility may require an impractically large 
number of subjects and will, in any case, put a greater number of subjects at risk (Carpenter 
et al., 2003; Miller, 2000). A 2005 trial of risperidone for acute mania conducted in India 
(Khanna et al., 2005) was criticized for unnecessarily exposing subjects to risk (Basil et al., 
2006; Murtagh and Murphy, 2006; Srinivasan et al., 2006). The investigators' response to 
criticisms adopted exactly the line of argument just described:
A placebo group was included because patients with mania generally show a high 
and variable placebo response, making it difficult to identify their responses to an 
active medication. Placebo-controlled trials are valuable in that they expose the 
fewest patients to potentially ineffective treatments. In addition, inclusion of a 
placebo arm allows a valid evaluation of adverse events attributable to treatment v. 
those independent of treatment. (Khanna et al., 2006)
Concerns about the standard of care given to research participants are exacerbated in trials in 
developing countries, like India, where research participants may not have access to 
treatment independent of the study. In such cases, potential participants may have no real 
choice but to join a placebo-controlled trial, for example, because that is the only way they 
have a chance to receive treatment. In the Indian risperidone trial, the issue of exploitation is 
particularly stark because it seemed to some that participants were getting less than the 
international best standard of care, in order that a pharmaceutical company could gather data 
that was unlikely to benefit many Indian patients.
This is just one way in which trial design may present ethically troubling risks to 
participants. Other potentially difficult designs include washout studies, in which 
participants discontinue use of their medication, and challenge studies, in which psychiatric 
symptoms are experimentally induced (Miller and Rosenstein, 1997). In both cases, the 
welfare of participants may seem to be endangered (Zipursky, 1999). A variant on the 
standard placebo-controlled trial design is the withdrawal design, in which everyone starts 
the trial on medication, the people who respond to the medication are then selected for 
randomization, and then half of those people are randomized to placebo. This design was 
used by a Japanese research team to assess the effectiveness of sertraline for depression, as 
described by Shimon Tashiro and colleagues in this collection. The researchers regarded this 
design as more likely to benefit the participants because for legal reasons, sertraline was 
being tested in Japan despite its proven effectiveness in non-Japanese populations. Tashiro 
and colleagues analyze how the risks and benefits of a withdrawal design compare with 
those of standard placebo-controlled trials and consider whether the special regulatory 
context of Japan makes a difference.
Study Population
The choice of study population implicates considerations of justice. The Belmont Report, 
which lays out the ethical foundations for the United States system for ethical review of 
human subject research, says:
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Individual justice in the selection of subjects would require that researchers … 
should not offer potentially beneficial research only to some patients who are in 
their favor or select only “undesirable” persons for risky research. Social justice 
requires that distinction be drawn between classes of subjects that ought, and ought 
not, to participate in any particular kind of research, based on the ability of 
members of that class to bear burdens and on the appropriateness of placing further 
burdens on already burdened persons. (National Commission for the Protection of 
Human Subjects of Biomedical and Behavioral Research, 1978)
Two distinct considerations are highlighted here. The first (“individual justice”) requires that 
the researchers treat people equally. Morally irrelevant differences between people should 
not be the basis for deciding whom to enroll in research. For example, it would normally be 
unjust to exclude women from a phase 3 trial of a novel treatment of early-stage Alzheimer 
disease, given that they are an affected group. Some differences are not morally irrelevant, 
however. In particular, there may be scientific reasons for choosing one possible research 
population over another, and there may be risk-related reasons for excluding certain groups. 
For example, a functional magnetic resonance imaging study in healthy volunteers to 
examine the acute effects of an antianxiety medication might reasonably exclude left-handed 
people because their brain structure is different from that of right-handed people, and a study 
of mood that required participants to forego medication could justifiably exclude people 
with severe depression or suicidal ideation.
The second consideration requires that we consider how the research is likely to impact 
“social justice.” Social justice refers to the way in which social institutions distribute goods, 
like property, education, and health care. This may apply to justice within a state (Rawls, 
1971) or to global justice (Beitz, 1973). In general, research will negatively affect social 
justice when it increases inequality, for example, by making people who are already badly 
off even worse off. The quotation from the Belmont Report above suggests one way in 
which research might violate a requirement of social justice: people who are already badly 
off might be asked to participate in research and so be made worse off. For example, a study 
examining changes in the brain caused by alcohol abuse that primarily enrolled homeless 
alcoholics from a shelter near the study clinic might only put at further risk this group who 
are already very badly off. An alternative way in which research can promote justice or 
injustice is through its results. Research that leads to the development of expensive new 
attention deficit hyperactivity disorder medication is likely to do little, if anything, to make 
the world more just. Research on how to improve the cognitive development of orphaned 
children in poor environments (like the BEIP) is much more likely to improve social justice.
This last point suggests a further concern about fairness—exploitation—that frequently 
arises in the context of international collaborative research in developing countries. 
Exploitation occurs, roughly, when one party takes “unfair advantage” of the vulnerability 
of another. This means that the first party benefits from the interaction and does so to an 
unfair extent (Wertheimer, 1996). These conditions may be met in international 
collaborative research when the burdens of research fall disproportionately on people and 
institutions in developing countries, but the benefits of research, such as access to new 
treatments, accrue to people in richer countries. A number of case studies in this collection 
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raise this concern in one way or another. For example, Virginia Rodriguez analyzes a 
proposed study of the genetic basis of antisocial personality disorder run by US researchers 
but carried out at sites in several Latin American countries. One of the central objections 
raised by one of the local national research ethics committees with regard to this study was 
that there appeared to be few, if any, benefits for patients and researchers in the host 
country.
Risks and Benefits
Almost all research poses some risk of harm to participants. Participants in mental health 
research may be particularly susceptible to risk in several ways. First, and most obviously, 
they may be physically or psychologically harmed as a result of trial participation. For 
example, an intervention study of an experimental antipsychotic may result in some serious 
adverse effects for participants who take the drug. Less obvious but still very important are 
the potential effects of stopping medication. As mentioned above, some trials of 
psychoactive medications require that patients stop taking the medications that they were on 
before the trial (e.g., the Japanese withdrawal trial). Stopping their medication can lead to 
relapse, to dangerous behavior (like attempted suicide), and could mean that their previous 
treatment regimen is less successful when they attempt to return to it. Participants who were 
successfully treated during a trial may have similar effects if they do not have access to 
treatment outside of the trial. This is much more likely to happen in research conducted with 
poor populations, such as the Indian mania patients.
The harms resulting directly from research-related interventions are not the only risk to 
participants in mental health research. Participation can also increase the risks of 
psychosocial harms, such as being identified by one's family or community as having a 
particular condition. Such breaches of confidentiality need not involve gross negligence on 
the part of researchers. The mere fact that someone regularly attends a clinic or sees a 
psychiatrist could be sufficient to suggest that they have a mental illness. In other research, 
the design makes confidentiality hard to maintain. For example, the genetic research 
described by Rodriguez involved soliciting the enrollment of the family members of people 
with antisocial personality disorder.
The harm from a breach of confidentiality is exacerbated when the condition studied or the 
study population is stigmatized. Both of these were true in the case Sana Loue describes in 
this collection. She studied the co-occurrence of severe mental illnesses and human 
immunodeficiency virus risk in African-American men who have sex with men. Not only 
was there shame attached to the conditions under study, such that they were euphemistically 
described in the advertisements for the research, but also many of the participants were men 
who had heterosexual public identities.
Informed Consent
Many people with mental disorders retain the capacity (ability) and competence (legal 
status) to give informed consent. Conversely, potential participants without mental problems 
may lack or lose capacity (and competence). Nevertheless, problems with the ability to 
consent remain particularly pressing with regard to mental health research. This is partly a 
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consequence of psychological conditions that reduce or remove the ability to give informed 
consent. To study these conditions, it may be necessary to use participants who have them, 
which means that alternative participants who can consent are, in principle, not available. 
This occurred in the study of South African stroke patients described by Anne Pope in this 
collection. The researcher she describes wanted to compare the effectiveness of exercises 
designed to help patients whose ability to communicate was compromised by their stroke. 
Given their communication difficulties and the underlying condition, there would inevitably 
be questions about their capacity. Whether it is permissible to enroll people who cannot give 
informed consent into a study depends on several factors, including the availability of 
alternative study populations, the levels of risk involved, and the possible benefits to 
participants in comparison with alternative health care they could receive.
In research that expects to enroll people with questionable capacity to consent, it is wise to 
institute procedures for assessing the capacity of prospective participants. There are two 
general strategies for making these assessments. The first is to conduct tests that measure the 
general cognitive abilities of the person being assessed, as an IQ test does. If she has the 
ability to perform these sorts of mental operations sufficiently well, it is assumed that she 
also has the ability to make autonomous decisions about research participation. A Mini-
Mental State Examination might be used to make this sort of assessment (Kim and Caine, 
2002). The second capacity assessment strategy focuses on a prospective participant's 
understanding and reasoning with regard to the specific research project they are deciding 
about. If she understands that project and what it implies for her and is capable of 
articulating her reasoning about it, then it is clear that she is capable of consenting to 
participation, independent of her more general capacities. This sort of assessment requires 
questions that are tailored to each specific research project and cannot be properly carried 
out unless the assessor is familiar with that research.
Where someone lacks the capacity to give consent, sometimes a proxy decision maker can 
agree to trial participation on her behalf. In general, proxy consent is not equivalent to 
individual consent: unless the proxy was expressly designated to make research decisions by 
the patient while capacitated, the proxy lacks the power to exercise the patient's rights. As a 
result, the enrollment of people who lack capacity is only acceptable when the research 
poses a low net risk to participants or holds out the prospect of benefiting them. When 
someone has not designated a proxy decision maker for research, it is common to allow the 
person who has the power to make decisions about her medical care also to make decisions 
about research participation. However, because medical care is directed at the benefit of the 
patient, but research generally is not aimed at the benefit of participants, the basis for this 
assumption is unclear. Its legal basis may be weak, too. For example, in her discussion of 
research on South African stroke patients, Pope notes the confusion surrounding the legality 
of surrogate decision makers, given that the South African constitution forbids proxy 
decision making for adults (unless they have court-appointed curators), but local and 
international guidance documents seem to assume it.
Although it is natural to think of the capacity to give consent as an all-or-nothing 
phenomenon, it may be better conceptualized as domain-specific. Someone may be able to 
make decisions about some areas of her life, but not others. This fits with assumptions that 
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many people make in everyday life. For example, a 10-year-old child may be deemed 
capable of deciding what clothes she will wear but may not be capable of deciding whether 
to visit the dentist. The capacity to consent may admit of degrees in another way, too. 
Someone may have diminished capacity to consent but still be able to make decisions about 
their lives if given the appropriate assistance. For example, a patient with mild dementia 
might not be capable of deciding on his own whether he should move in with a caregiver, 
but his memory lapses during decision making could be compensated for by having his son 
present to remind him of details relevant to the decision. The concept of supported decision 
making has been much discussed in the literature on disability; however, its application to 
consent to research has received little attention (Herr, 2003; United Nations, 2007).
The ability to give valid informed consent is the aspect of autonomy that is most frequently 
discussed in the context of mental health research, but it is not the only important aspect. 
Several of the case studies in this collection also raise issues of voluntariness and coercion. 
For example, Douglas Wassenaar and Nicole Mamotte describe a study in which professors 
enrolled their students, which raises the question of the vulnerability of student subjects to 
pressure. Here, there is both the possibility of explicit coercion and the possibility that 
students will feel pressure even from well-meaning researchers. For various reasons, 
including dependence on caregivers or healthcare professionals and the stigma of their 
conditions, people with mental illnesses can be particularly vulnerable to coercion.
Post-Trial Obligations
The obligations of health researchers extend past the end of their study. Participants'data 
remain in the hands of researchers after their active involvement in a study is over, and 
patients with chronic conditions who enroll in clinical trials may leave them still in need of 
treatment.
Ongoing confidentiality is particularly important when studying stigmatized populations 
(such as men who have sex with men as discussed by Sana Loue) or people with 
stigmatizing conditions (such as bipolar disorder). In research on mental illnesses, as with 
many medical conditions, it is now commonplace for researchers to collect biological 
specimens and phenotypic data from participants to use in future research (such as genome-
wide association studies). Additional challenges with regard to confidentiality are raised by 
the collection of data and biological specimens for future research because confidentiality 
must then be guaranteed in a long period of time and frequently with different research 
groups making use of the samples.
Biobanking also generates some distinctive ethical problems of its own. One concerns how 
consent to the future use of biological specimens should be obtained. Can participants 
simply give away their samples for use in whatever future research may be proposed, or do 
they need to have some idea of what this research might involve in order to give valid 
consent? A second problem, which arises particularly in transnational research, concerns 
who should control the ongoing use of the biobank. Many researchers think that biological 
samples should not leave the country in which they were collected, and developing country 
researchers worry that they will not be allowed to do research on the biobanks that end up in 
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developed countries. This was another key concern with the proposed study in Latin 
America.
In international collaborative research, further questions arise as a result of the disparities 
between developing country participants and researchers and developed country sponsors 
and researchers. For example, when clinical trials test novel therapies, should successful 
therapies be made available after the trial? If they should, who is responsible for ensuring 
their provision, to whom should they be provided, and in what does providing them consist? 
In the case of chronic mental illnesses like depression or bipolar disorder, patient-
participants may need maintenance treatment for the rest of their lives and may be at risk if 
treatment is stopped. This suggests that the question of what happens to them after the trial 
must at least be considered by those who sponsor and conduct the trial and the regulatory 
bodies that oversee it. Exactly on whom obligations fall remains a matter of debate (Millum, 
2011).
Ethics Guidelines
A number of important policy documents are relevant to the ethics of research into mental 
disorders. The WMA's Declaration of Helsinki and the CIOMS' Ethical Guidelines for 
Biomedical Research both consider research on individuals whose capacity and/or 
competence to consent is impaired. They agree on three conditions: a) research on these 
people is justified only if it cannot be carried out on individuals who can give adequate 
informed consent, b) consent to such research should be obtained from a proxy 
representative, and c) the goal of such research should be the promotion of the health of the 
population that the research participants represent (Council for International Organizations 
of Medical Sciences, 2002; World Medical Association, 2008). In addition, with regard to 
individuals who are incapable of giving consent, Guideline 9 of CIOMS states that 
interventions that do not “hold out the prospect of direct benefit for the individual subject” 
should generally involve no more risk than their “routine medical or psychological 
examination.”
In 1998, the US National Bioethics Advisory Commission (NBAC) published a report 
entitled Research Involving Persons with Mental Disorders That May Affect Decision-
making Capacity (National Bioethics Advisory Commission, 1998). As the title suggests, 
this report concentrates on issues related to the capacity or competence of research 
participants to give informed consent. Its recommendations are largely consistent with those 
made in the Declaration of Helsinki and CIOMS, although it is able to devote much more 
space to detailed policy questions (at least in the United States context). Two domains of 
more specific guidance are of particular interest. First, the NBAC report considers the 
conditions under which individuals who lack the capacity to consent may be enrolled in 
research posing different levels of risk and supplying different levels of expected benefits to 
participants. Second, it provides some analysis of who should be recognized as an 
appropriate proxy decision maker (or “legally authorized representative”) for participation in 
clinical trials.
Finally, the World Psychiatric Association's Madrid Declaration gives guidelines on the 
ethics of psychiatric practice. This declaration may have implications for what is permissible 
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in psychiatric research, insofar as the duties of psychiatrists as personal physicians are also 
duties of psychiatrists as medical researchers. It also briefly considers the ethics of 
psychiatric research, although it notes only the special vulnerability of psychiatric patients as 
a concern distinctive of mental health research (World Psychiatric Association, 2002).
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Table 1
Case Studies in the Ethics of Mental Health Research
Contributor Case Location Central Issues
Douglas Wassenaar and Nicole 
Mamotte Commentary by Robert 
Michels Commentary by 
Samantha Copeland
The use of students as participants in mental health 
research: Eating disorders in developing countries
South Africa Coercion, consent, researcher-
participant relationship
Shimon Tashiro, Maki M. 
Yamada, and Kenji Matsui
Ethical issues of placebo-controlled studies in 
depression: The case of a randomized withdrawal 
trial in Japan
Japan Comparative risks and benefits 
of different trial designs
Virginia Rodriguez Genetic screening for antisocial personality 
disorder
Latin America Fair subject selection, control of 
samples/data, capacity building
Anne Pope Qualitative research with adult stroke patients South Africa Legal vagueness, capacity to 
consent
Charles H. Zeanah Commentary 
by Annette Rid
The Bucharest early intervention project: A 
randomized controlled trial comparing foster care 
and institutionalization
Romania Fair subject selection, scientific 
value, equipoise, risk
Sana Loue Commentary by 
Douglas Brugge
The co-occurrence of bipolar disorder and human 
immunodeficiency virus risk among African-
American men who have sex with men
United States Stigma, confidentiality, 
community consultation, 
institutional review board review
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